BioCryst Pharmaceuticals Officer Charles Gayer Exercises Stock Options and Acquires Shares

Charles K. Gayer, President and CCO of BioCryst Pharmaceuticals Inc (BCRX), filed a Form 4 reporting significant stock transactions between December 19-22, 2025. On December 19, Gayer disposed of 11,477 shares at $7.41 per share through tax withholding for vested restricted stock units. On December 22, he exercised three separate employee stock option grants, acquiring 74,233 common shares total. The exercises included 14,142 shares at $3.22 per share, 10,091 shares at $5.04 per share, and 50,000 shares at $5.51 per share. Following these transactions, Gayer's total direct ownership increased to 952,583 shares. The options exercised had original grant dates ranging from 2017-2018 and were vesting over four years. This filing represents routine executive compensation activity involving option exercises and tax withholding on vested equity awards.